Trending News
News
News
Reliability of Serum Metabolite Concentrations over a 4-Month Period Using a Targeted Metabolomic Approach
Researchers have investigated the between- and within-person variation of the concentrations of 163 serum metabolites over a period of 4 months to evaluate the metabolite reliability expressed by the intraclass-correlation coefficient.
News
Absolute Quantification of Microbial Proteomes at Different States by Directed Mass Spectrometry
This paper details how researchers have performed the first study that describes the absolute quantitative behaviour of any proteome over multiple states.
News
MBio Diagnostics, Inc. Wins NIH Award for Flu Test Development
MBio Diagnostics, Inc. announces it has received an award from the US National Institutes of Health to detect disease-causing respiratory pathogens in humans.
News
New European Lab Automation Event Saw Outstanding Success
With 1523 attendees and 151 exhibitors and media partners, feedback from European Lab Automation was overwhelmingly positive.
News
VacChina 2011- The Largest China’s Vaccine Meeting
The meeting welcomes world class biotechs and pharmas to discuss the opportunities of development of novel vaccine R&D and manufacturing technologies in China.
News
Medgenics Signs Exclusive License Agreement for Key Variants of Factor VIII
Company signed an exclusive license with Regents of the University of Michigan of patent rights relating to certain uses of variants of clotting Factor VIII developed by Professor Randall Kaufman.
News
Medivir to Acquire BioPhausia
Strategic and complementary acquisition, significantly strengthening Medivir’s commercial capabilities in the Nordic Market.
News
Advion BioServices First to Offer SISCAPA Assay Services for Biomarker Assays
The SISCAPA assays are mass spectrometry-based, and will be conducted in Advion’s LC/MS laboratory.
News
Oncolytics Biotech® Inc. Announces Second Quarter 2011 Results
Company announces financial results and operational highlights for the quarter ended June 30, 2011.
News
PII Expands Drug Formulation and Manufacturing Capabilities With Hot Melt Extrusion Technology
Pii to carry out feasibility studies, using few grams of active pharmaceutical ingredient, to pilot scale cGMP productions for Phase I and II clinical trials using HME.
Advertisement